Skip to main content

Table 2 The computational methods included in this study

From: Uncovering the roles of microRNAs/lncRNAs in characterising breast cancer subtypes and prognosis

Abbreviation

# RNA

Cohort

Applicable data

Purpose

References

CC

–

BC

Multi-omics

Subtyping

[6]

CNMF

–

BC

Multi-omics

Subtyping

[7]

iCluster

–

BC

Multi-omics

Subtyping

[8]

IntClust

—

BC

mRNAs

\(\hbox {Subtyping}^1\)

[9]

SNF

–

BC

Multi-omics

Subtyping

[10]

SNF-CC

–

BC

Multi-omics

subtyping

[25]

WSNF

–

BC

mRNAs, miRNAs

Subtyping

[11]

CIMLR

–

BC

Multi-omics

Subtyping

[12]

PINS

–

BC

Multi-omics

Subtyping

[13]

NEMO

–

BC

Multi-omics

Subtyping

[14]

intNMF

–

BC

Multi-omics

Subtyping

[67]

PAM50

50

BC

mRNAs

\(\hbox {Subtyping}^1\)

[15]

rorS

50

BC

mRNAs

Prognosis

[15]

GENE70

70

ER+

mRNAs

Prognosis

[16]

OncotypeDX

21

ER+

mRNAs

Prognosis

[17]

GGI

97

ER+

mRNAs

Prognosis

[18]

Tamr13

181

ER+

mRNAs

Prognosis

[19]

AURKA

1

BC

mRNA

Prognosis

[20]

ESR1

1

BC

mRNA

Prognosis

[20]

ERBB2

1

BC

mRNA

Prognosis

[20]

GENIUS

314

BC

mRNAs

Prognosis

[21]

PIK3CAGS

278

ER+

mRNAs

Prognosis

[22]

EndoPredict

11

ER+

mRNAs

Prognosis

[23]

Ensemble

238

BC

mRNAs

Prognosis

Additional file 1

miR-21

1

BC

miRNA

Prognosis

[69,70,71]

miR-155

1

BC

miRNA

Prognosis

[72]

miR-210

1

BC

miRNA

Prognosis

[73, 74]

RNAmodel

37

BC

mRNAs, miRNAs

Prognosis

[38]

miRNA10

10

BC

miRNAs

Prognosis

[43]

HOTAIR

1

BC

lncRNA

Prognosis

[75]

MALAT1

1

BC

lncRNA

Prognosis

[76]

DSCAM-AS1

1

BC

lncRNA

Prognosis

[77]

lncRNA12

12

BC

lncRNAs

Prognosis

[39]

LncRNA6

6

ER+

lncRNAs

Prognosis

[40]

LncRNA5

5

BC

lncRNAs

Prognosis

[41]

  1. Abbreviations for prognostic methods are defined in Additional file 1. # RNA, number of RNA signatures used in methods; \(^1\), the method maps breast cancer patients to predefined subtypes; mRNA, messenger RNA; miRNA, microRNA; lncRNA, long non-coding RNA; BC, breast cancer; ER+, estrogen receptor-positive breast cancer